News | May 2, 2017

AMRI Receives NIH Contract Award For Drug Substance Development And Manufacturing Services

Albany, NY /PRNewswire/ - AMRI (NASDAQ: AMRI) today announced it received a 5-year federal contract award from the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), for drug substance development and manufacturing services. The NCATS award will support the Division of Pre-Clinical Innovation's (DPI) drug development programs by providing drug substance development and manufacturing services related to the synthesis and analysis of small molecules.

The goal of the DPI is to advance collaborative research projects across pre-clinical phases of the translational science spectrum. Through this contract AMRI will support the DPI scientists to advance early stage NCATS drug discovery projects from candidate nomination to clinical trials, by providing services related to process development, analytical development and GMP manufacture of small molecule drug candidates to support clinical trials.

"Our mission is to provide our customers a complete suite of services across the drug discovery, development and manufacturing continuum for the advancement of much needed medicines to improve patient outcomes," said Christopher Conway, senior vice president of Drug Discovery, Development and Analytical Services (DDS). "AMRI is confident that our track record of success in advancing programs from pre-clinical to commercial launch will support NIH's mission to translate scientific knowledge into effective therapies."

About AMRI
AMRI is a global contract research and manufacturing organization that has been working with the life sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP), and Fine Chemicals. For more information about AMRI, please visit our website at or follow us on Twitter (@amriglobal).

AMRI Forward-Looking Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "will," "may," "intends," "anticipate," "plan," "enables," "potentially," "expects," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include, but are not limited to: statements regarding the goals of the DPI, AMRI's expected future performance pursuant to the NIH contract award and the likelihood that the NIH contract award will ultimately result in approved and effective therapies. All such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond AMRI's control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Such risks include, but are not limited to: whether AMRI will successfully perform under the NIH contract award; the continuation of the DPI drug development programs under which AMRI is providing services; whether AMRI's services will ultimately result in approved and effective therapies; as well as those risks that are discussed in AMRI's Annual Report on Form 10-K for the fiscal year ended December 31, 2016 as filed with the U.S. Securities and Exchange Commission on March 16, 2017 and other subsequent filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and AMRI does not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.


Copyright 2017 PR Newswire. All Rights Reserved